To further evaluate if systemic β-lap treatment has any immunosuppressive effects and impairs anti-PD-L1 immunotherapy, MC38 tumor-bearing mice were administrated with systemic β-lap treatment (30 mg/kg, i.p.)monotherapy or combined with anti-PD-L1 (Fig. 6d). This evidence concerns the gene CD274 and neoplasm.